Impact of Total Ischemic Time on No Reflow Phenomenon
Article Sidebar
Main Article Content
Abstract
Background: Ischemic heart disease, particularly ST-segment elevation myocardial infarction (STEMI), remains a major cause of morbidity and mortality globally. Despite advancements in primary percutaneous coronary intervention (PPCI), the no-reflow phenomenon, characterized by inadequate myocardial reperfusion despite successful vessel recanalization, continues to pose significant challenges, affecting clinical outcomes adversely.
Objective: This study aims to investigate the relationship between total ischemic time and the incidence of the no-reflow phenomenon in STEMI patients undergoing PPCI, to identify potential strategies for improving therapeutic outcomes.
Methods: Conducted at Hayatabad Medical Complex, Peshawar, this retrospective cohort study included 160 STEMI patients treated over eight months (February to October 2022). We collected data on demographic characteristics, clinical presentation, and outcomes. Inclusion criteria were patients over 18 years, undergoing PPCI within 12 hours of symptom onset, without prior MI, severe bleeding disorders, or previous significant revascularization. Statistical analysis was performed using SPSS 25.0, considering P ≤0.05 as statistically significant.
Results: The average total ischemic time was significantly longer in patients experiencing no-reflow (Group I, 7.91 hours) compared to those with normal reperfusion (Group II, 3.41 hours) (P=0.001). Group I also showed higher rates of cardiogenic shock (17.6% vs. 6.8%, P=0.012) and reinfarction (11.8% vs. 2.9%, P=0.010). Mortality was significantly higher in Group I (5.8% vs. 1.9%, P=0.020).
Conclusion: Longer total ischemic time is associated with an increased risk of the no-reflow phenomenon and poorer clinical outcomes in STEMI patients. Reducing ischemic time could be crucial in improving reperfusion success and reducing complications post-PPCI.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics–2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):e139–596. doi: 10.1161/CIR.0000000000000757.
Foo CY, Bonsu KO, Nallamothu BK, Reid CM, Dhippayom T, Reidpath DD, et al. Coronary Intervention Door-to-Balloon Time and Outcomes in ST-Elevation Myocardial Infarction: A Meta-Analysis. Heart. 2018;104(16):1362–9. doi: 10.1136/heartjnl-2017-312517.
Kawecki D, Morawiec B, Gąsior M, Wilczek K, Nowalany-Kozielska E, Gierlotka M. Annual Trends in Total Ischemic Time and One-Year Fatalities: The Paradox of STEMI Network Performance Assessment. Journal of Clinical Medicine. 2019;8(1):78. doi: 10.3390/jcm8010078.
Kim HK, Jeong MH, Ahn Y, Chae SC, Kim YJ, Hur SH, et al. Relationship Between Time to Treatment and Mortality Among Patients Undergoing Primary Percutaneous Coronary Intervention According to Korea Acute Myocardial Infarction Registry. Journal of Cardiology. 2017;69(1):377–82. doi: 10.1016/j.jjcc.2016.09.002.
Chandrasekhar J, Marley P, Allada C, McGill D, O’Connor S, Rahman M, et al. Symptom-to-Balloon Time is a Strong Predictor of Adverse Events Following Primary Percutaneous Coronary Intervention: Results From the Australian Capital Territory PCI Registry. Heart, Lung and Circulation. 2017;26(1):41–8. doi: 10.1016/j.hlc.2016.05.114.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H. 2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation: The Task Force for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018;39(2):119–77. doi: 10.1093/eurheartj/ehx393.
Kuznetsov VA, Yaroslavskaya EI, Pushkarev GS, Zyryanov IP, Bessonov IS, Gorbatenko EA, et al. Interrelation of Transcutaneous Coronary Interventions for Acute Forms of Coronary Heart Disease and Mortality Parameters in Tyumen Region Inhabitants. Russian Journal of Cardiology. 2014;19(6):42–6.
Nallamothu BK, Normand S-LT, Wang Y, Hofer TP, Brush JE, Messenger JC, et al. Relation Between Door-to-Balloon Times and Mortality After Primary Percutaneous Coronary Intervention Over Time: A Retrospective Study. The Lancet. 2015;385(9973):1114–22. doi: 10.1016/S0140-6736(14)61932-2.
Khalid U, Jneid H, Denktas AE. The Relationship Between Total Ischemic Time and Mortality in Patients With STEMI: Every Second Counts. Cardiovascular Diagnosis and Therapy. 2017;7(S2):S119–24. doi: 10.21037/cdt.2017.05.10.
Solhpour A, Chang K-W, Arain SA, Balan P, Loghin C, McCarthy JJ, et al. Ischemic Time Is a Better Predictor Than Door-to-Balloon Time for Mortality and Infarct Size in ST-Elevation Myocardial Infarction: Ischemic Time Is Better Than Door to Balloon Time. Catheterization and Cardiovascular Interventions. 2016;87(7):1194–200. doi: 10.1002/ccd.26230.
Song F, Yu M, Yang J, Xu H, Zhao Y, Li W, et al. Symptom-Onset-To-Balloon Time, ST-Segment Resolution and In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention in China: From China Acute Myocardial Infarction Registry. The American Journal of Cardiology. 2016;118(9):1334–9. doi: 10.1016/j.amjcard.2016.07.058.
Mujanovic A, Ng F, Meinel TR, Dobrocky T, Piechowiak EI, Kurmann CC, Seiffge DJ, Wegener S, Wiest R, Meyer L, Fiehler J. No-reflow phenomenon in stroke patients: a systematic literature review and meta-analysis of clinical data. International Journal of Stroke. 2024 Jan;19(1):58-67.
Rashid MK, Guron N, Bernick J, Wells GA, Blondeau M, Chong A-Y, et al. Safety and Efficacy of a Pharmacoinvasive Strategy in ST-Segment Elevation Myocardial Infarction: A Patient Population Study Comparing a Pharmacoinvasive Strategy with a Primary Percutaneous Coronary Intervention Strategy Within a Regional System. JACC: Cardiovascular Interventions. 2016;9(19):2014–20. doi: 10.1016/j.jcin.2016.07.004.
Bessonov IS, Kuznetsov VA, Zyryanov IP, Musikhina NA, Sapozhnikov SS, Takkand AG, et al. Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction With ST-Segment Elevation After Prehospital Thrombolysis. Kardiologiia. 2016;56(2):5–10.
Auffret V, Laurin C, Leurent G, Didier R, Filippi E, Hacot J-P, et al. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction in Patients ≥70 Years of Age. The American Journal of Cardiology. 2020;125(1):1–10. doi: 10.1016/j.amjcard.2019.09.044.
Jia M, Jin F, Li S, Ren C, Ruchi M, Ding Y, Zhao W, Ji X. No‐reflow after stroke reperfusion therapy: An emerging phenomenon to be explored. CNS Neuroscience & Therapeutics. 2024 Feb;30(2):e14631.
Lawesson SS, Isaksson R-M, Thylén I, Ericsson M, Ängerud K, Swahn E. Gender Differences in Symptom Presentation of ST-Elevation Myocardial Infarction – An Observational Multicenter Survey Study. International Journal of Cardiology. 2018;264:7–11. doi:10.1016/j.ijcard.2018.03.084.
Kennedy SR, Kim Y, Martin S, Rose SJ. Total ischemic time and age as predictors of PCI failure in STEMIs: A systematic review. The American Journal of the Medical Sciences. 2023 Jun 17.
Nielsen CG, Laut KG, Jensen LO, Ravkilde J, Terkelsen CJ, Kristensen SD. Patient Delay in Patients With ST-Elevation Myocardial Infarction: Time Patterns and Predictors for a Prolonged Delay. European Heart Journal: Acute Cardiovascular Care. 2017;6(7):583–91. doi: 10.1177/2048872616676570.
Bamarinejad A, Kermani-Alghoraishi M, Soleimani A, Roohafza H, Yazdekhasti S, MirmohammadSadeghi A, Bamarinejad F, Sadeghi M. Long-term outcome and prognostic value of angiographic slow/no-reflow phenomenon after emergency percutaneous coronary intervention for ST-elevation myocardial infarction. Coronary Artery Disease. 2024 Apr 2:10-97.